Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Endogenous opiates may affect various aspects of reproductive and metabolic function in patients with polycystic ovary syndrome (PCOS). This study evaluated long-term inhibition of the opioid system using naltrexone in clomiphene citrate (CC)-resistant women with PCOS. METHODS: A group of 30 infertile females with PCOS were evaluated; all subjects were obese, hyperandrogenic and hyperinsulinemic; 16 patients were amenorrhic and 14 were oligomenorrhic. All subjects received natrexone (50 mg p.o. daily) for 6 months. Patients who did not ovulate after 12 weeks of naltrexone monotherapy, also received CC (starting at 50 mg/day for 5 days and, for non-responders, increasing it up to 150 mg/day). RESULTS: Of the 30 women, 3 ovulated during naltrexone monotherapy and 19 of the remaining 27 ovulated during naltrexone + CC therapy. There were no conceptions during naltrexone monotherapy, but 9 of 27 women (33.3%) conceived during naltrexone + CC; there was one missed abortion at 9 weeks, one preterm delivery at 34 weeks and seven term live births. Naltrexone therapy was also followed by significant reductions in BMI, fasting serum insulin, luteinizing hormone (LH), LH/follicle-stimulating hormone ratio and testosterone. CONCLUSIONS: In this preliminary trial, naltrexone improved endocrine and metabolic function in women with CC-resistant PCOS. Furthermore, naltrexone restored CC sensitivity in the majority of subjects, resulting in a significant number of pregnancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although some studies have been inconclusive,75,76 the opioid antagonist naltrexone is effective in reducing endocrine symptoms in women with PCOS,77–79 also suggesting that high β-endorphin levels are a feature of this condition.”
From Prenatal Origins of Endometriosis Pathology and Pain: Reviewing the Evidence of a Role for Low Testosterone (2023) · cites this paper as [78]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Prevalence of PCOS has been studied in several populations and it appears that it affects as many as 5–10% of women of reproductive age (Diamanti-Kandarakis et al., 1999; Azziz et al., 2004).”
BackgroundCLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMEN
FERRIMAN, D., & GALLWEY, J. D. (1961) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,506 · cited 2×
“METHODS: A group of 30 infertile females with PCOS were evaluated; all subjects were obese, hyperandrogenic and hyperinsulinemic; 16 patients were amenorrhic and 14 were oligomenorrhic.”
BackgroundMethodDiamanti‐Kandarakis, E., Kouli, C., Bergiele, A. T., Filandra, F. A., Tsianateli, T. C., Spina, G., Zapanti, E. D., & Bartzis, M. I. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.11.4006 · Cited by 1,110 · cited 1×
“Prevalence of PCOS has been studied in several populations and it appears that it affects as many as 5–10% of women of reproductive age (Diamanti-Kandarakis et al., 1999; Azziz et al., 2004).”
BackgroundPrevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.
Adams, J., Polson, D. W., & Franks, S. (1986) · BMJ · doi:10.1136/bmj.293.6543.355 · Cited by 981 · cited 1×
“Polycystic ovarian morphology was diagnosed as the presence of more than 12 follicles (2004) with diameter 8 mm arranged peripherally or scattered throughout an echodense core of stroma (Adams et al., 1986; Polson et al., 1988).”
BackgroundPOLYCYSTIC OVARIES—A COMMON FINDING IN NORMAL WOMEN
Polson, D. W., Wadsworth, J., Adams, J., & Franks, S. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91612-1 · Cited by 906
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · cited 2×
“These effects may be related to a decreased LH and improvement of hyperinsulinemia, resulting in lower ovarian androgen production (Nestler and Jakubowicz, 1996).”
BackgroundLegro, R. S., Finegood, D., & Dunaif, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5054 · Cited by 673 · cited 2×
“5 mg/unit are consistent with insulin resistance (Legro et al., 1998).”
BackgroundInfluential
Research works printed but not linked: 3
- Guido, 1998, Journal of Clinical Endocrinology & Metabolism, 83, 1742, 10.1210/jc.83.5.1742 · doi:10.1210/jc.83.5.1742
- Malcolm, 1986, NIDA research monograph, 75, 371
- 1988, 1, 870
Cited by
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Jedel, E., Labrie, F., Odén, A., Holm, G., Nilsson, L., Janson, P. O., Lind, A.-K., Ohlsson, C., & Stener-Victorin, E. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00495.2010 · Cited by 223
Polycystic Ovary Syndrome: Effect and Mechanisms of Acupuncture for Ovulation Induction
Johansson, J., & Stener‐Victorin, E. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/762615 · Cited by 150
Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial
Johansson, J., Redman, L., Veldhuis, P. P., Sazonova, A., Labrie, F., Holm, G., Johannsson, G., & Stener-Victorin, E. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00039.2013 · Cited by 131
Androgens and polycystic ovary syndrome
Nisenblat, V., & Norman, R. J. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832afd4d · Cited by 125
A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 103
Mannerås, L., Cajander, S., Lönn, M., & Stener-Victorin, E. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90947.2008 · Cited by 94
Neuroendocrine Determinants of Polycystic Ovary Syndrome
Szeliga, A., Rudnicka, E., Maciejewska-Jeske, M., Kucharski, M., Kostrzak, A., Hajbos, M., Niwczyk, O., Smolarczyk, R., & Męczekalski, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19053089 · Cited by 101
“Studies conducted on the use of opioid antagonists, naltrexone and naloxone for the treatment of PCOS, found that this kind of therapy significantly reduced the insulin response to oral glucose tolerance test (OGTT) in a group of hyperinsulinemic patients with PCOS [76].”
BackgroundThe physiological basis of complementary and alternative medicines for polycystic ovary syndrome
Raja-Khan, N., Stener-Victorin, E., Wu, X., & Legro, R. S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00667.2010 · Cited by 86
“Effect of electro-acupuncture on ovarian expression of alpha(1)- and”
BackgroundJohansson, J., Feng, Y., Shao, R., Lönn, M., Billig, H., & Stener‐Victorin, E. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2010 · Cited by 86
“Interestingly, naltrexone, another -receptor antagonist, improves cyclicity, induces ovulation, and decreases LH, the LH/FSH ratio, and testosterone levels in women with PCOS (1, 24).”
BackgroundThe Emerging Therapeutic Potential of Kisspeptin and Neurokinin B
Patel, B., Koysombat, K., Mills, E., Tsoutsouki, J., Comninos, A. N., Abbara, A., & Dhillo, W. S. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad023 · Cited by 72
Feng, Y., Johansson, J., Shao, R., Mannerås, L., Fernández-Rodríguez, J., Billig, H., & Stener‐Victorin, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006638 · Cited by 67
“Evidence that b-endorphin participates in the regulation of GnRH/LH secretion in PCOS comes from a recent trial in women with PCOS, in which naltrexone, a mu-receptor antagonist, induced ovulation and decreased LH levels, the LH/FSH ratio, and testosterone levels [42].”
BackgroundTreatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS)
Garg, A., Patel, B., Abbara, A., & Dhillo, W. S. (2022) · Clinical Endocrinology · doi:10.1111/cen.14704 · Cited by 72
Medical management of metabolic dysfunction in PCOS
Duleba, A. J. (2012) · Steroids · doi:10.1016/j.steroids.2011.11.014 · Cited by 60
“In three of these studies, orlistat improved parameters of insulin sensitivity and reduced insulin level with concomitant decrease of BMI [46,47,49].”
BackgroundImmunology and Immunotherapy of Endometriosis
Maksym, R., Hoffmann, M., Skibińska, M., Rabijewski, M., Mackiewicz, A. A., & Kiéda, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245879 · Cited by 66
“In the majority of patients with pelvic pain syndrome, LDN therapy allowed at least a stabilization or reduction in symptoms without compromising fertility [61,62].”
BackgroundPalomba, S., Falbo, A., & Zullo, F. (2009) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328332d188 · Cited by 61
Effects and mechanisms of acupuncture in the reproductive system
Stener‐Victorin, E., & Wu, X. (2010) · Autonomic Neuroscience · doi:10.1016/j.autneu.2010.03.006 · Cited by 57
“Evidence that β-endorphin contributes to the pathogenesis of PCOS and dysregulation of GnRH/LH secretion comes from studies showing that the μ-receptor antagonists naltrexone or naloxone improve menstrual cyclicity, induced ovulation, and decrease insulin and LH levels, the LH/follicle stimulating hormone (FS) ratio,…”
The role of the endogenous opioid system in polycystic ovary syndrome
Eyvazzadeh, A. D., Pennington, K. P., Pop‐Busui, R., Sowers, M., Zubieta, J., & Smith, Y. R. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.05.012 · Cited by 56
The evolutionary biology of endometriosis
Dinsdale, N., Nepomnaschy, P., & Crespi, B. (2021) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoab008 · Cited by 53
Feng, Y., Johansson, J., Shao, R., Mannerås-Holm, L., Billig, H., & Stener‐Victorin, E. (2012) · Experimental Physiology · doi:10.1113/expphysiol.2011.063131 · Cited by 57
“Furthermore, in anovulatory women with PCOS, the μ-opioid receptor antagonist naltrexone induces ovulation and decreases LH concentration, the ratio of LH to follicle-stimulating hormone, and testosterone levels; these findings support the hypothesis that PCOS is associated with elevated βendorphin secretion (Ahmed et…”
ResultXi, W., Yang, Y.-K., Mao, H. Z., Zhao, X., Liu, M., & Fu, S. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0214-2 · Cited by 51
“Definitions vary the dose required to define CC-resistance ranging from 100 mg to150 mg of CC [27, 28].”
Johansson, J., Mannerås-Holm, L., Shao, R., Olsson, A., Lönn, M., Billig, H., & Stener‐Victorin, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054357 · Cited by 41
“This effect may be related, at least in part, to the release of b-endorphin [52,53].”
BackgroundEndogenous opiates and behavior: 2008
Bodnar, R. J. (2009) · Peptides · doi:10.1016/j.peptides.2009.09.027 · Cited by 49
Metabolic treatment of cancer: intermediate results of a prospective case series.
Schwartz, L. H., Ludivine, B., Icard, P., Lincet, H., & Steyaert, J. (2014) · PubMed · Cited by 44
Ilie, I. R. P. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.11.004 · Cited by 37
Stener‐Victorin, E. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.006 · Cited by 29
“levels (Ahmed et al., 2008; Ciampelli et al., 1998; Fruzzetti et al., 2002; Fulghesu et al., 1998; Hadziomerovic et al., 2006; Lanzone et al., 1995).”
Gurule, S. C., Sustaita-Monroe, J. F., Padmanabhan, V., & Cardoso, R. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1096187 · Cited by 28
Zangeneh, F. Z., Mohammadi, A., Ejtemaeimehr, S., Naghizadeh, M. M., & Aminee, F. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1776-7 · Cited by 22
Baranowska-Bik, A. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0047 · Cited by 21
“Interestingly, in PCOS, monotherapy with naltrexone for 6 months resulted in a marked decrease in BMI, fasting serum insulin, LH levels, LH/FSH ratio, and testosterone concentration [41].”
BackgroundInsulin resistance influences central opioid activity in polycystic ovary syndrome
Berent‐Spillson, A., Love, T., Pop‐Busui, R., Sowers, M. R., Persad, C. C., Pennington, K. P., Eyvazzadeh, A. D., Padmanabhan, V., Zubieta, J., & Smith, Y. R. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.03.031 · Cited by 20
Opioid-Induced Endocrinopathy in Cancer Patients: An Underestimated Clinical Problem
Buss, T., & Leppert, W. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0096-x · Cited by 20
“antagonist naltrexone may induce ovulation in women with PCOS and result in conception by LH surge [40].”
BackgroundMetformin increases pressure pain threshold in lean women with polycystic ovary syndrome
Кялка, М., Milewicz, T., Sztefko, K., Rogatko, I., & Majewska, R. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s109086 · Cited by 18
Crespi, B. J., & Evans, S. F. (2023) · Journal of Pain Research · doi:10.2147/jpr.s389166 · Cited by 17
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine
McIntyre, R. S., Citrome, L., Cummings, H., Todtenkopf, M. S., Tan, L. A., Harris‐White, M. E., & Akerman, S. C. (2022) · CNS Spectrums · doi:10.1017/s1092852922000116 · Cited by 15
Wang, Q., Zhang, Q., Lu, F., Hu, H., & Zhu, M. (2024) · Journal of Pain Research · doi:10.2147/jpr.s441512 · Cited by 12
Mechanisms and predictors of menses resumption once normal weight is reached in anorexia nervosa
Galusca, B., Gay, A., Belleton, G., Eisinger, M., Massoubre, C., Lang, F., Grouselle, D., Estour, B., & Germain, N. (2023) · Journal of Eating Disorders · doi:10.1186/s40337-023-00893-x · Cited by 10
Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets
Shirasath, K. R., Ahmed, N. Z., Kumar, P., Alam, S., Karwasra, R., Goyal, S. N., & Agrawal, Y. O. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156245 · Cited by 7
Metabolic dysfunctions in polycystic ovary syndrome
Rahman, M., Rahman, F. T., Mallik, M. U., Saha, J., Rahman, M. M., & Azad, K. A. K. (2024) · Journal of Medicine · doi:10.3329/jom.v25i1.70703 · Cited by 8
“The same results were achieved with GnRH antagonist use 23,25 .”
BackgroundThe Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome
Chatzis, P., Τζιόμαλος, Κ., Pratilas, G. C., Makris, V., Sotiriadis, A., & Dinas, K. D. (2018) · Folia Medica · doi:10.2478/folmed-2018-0036 · Cited by 8
Effects of naloxone and yohimbine in polycystic ovary syndrome: a rabbit model study
Sajjad, S., Tobassum, S., Farooq, U., Malik, H., & İdris, M. (2016) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1412-77 · Cited by 8
Roy, P., Agrawal, P. K., Gupta, P. K., Garg, R., & Srivastava, J. (2023) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-2195 · Cited by 5
“46 Acne, hirsutism, and amenorrhea were shown to be improved by naltrexone, and it was also reported to lower serum testosterone and insulin levels while regaining sensitivity to clomiphene citrate in patients who were resistant to it.”
Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder
Bello, J. K., Xu, K. Y., Salas, J., Bedrick, B. S., & Grucza, R. A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08689-8 · Cited by 2
Kelty, E. A. (2012) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000105 · Cited by 2
“Due to the opioid systems interactions with other systems, naltrexone has become a drug of interest in a number of different areas of research including substance dependence [1-3], autoimmune diseases such as Crohn’s disease [4] and multiple sclerosis [5,6], compulsive behaviours such as kleptomania [7] and self-injur…”
BackgroundTakahashi, T., Igarashi, H., Hara, S., Amita, M., Matsuo, K., Hasegawa, A., & Kurachi, H. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-74 · Cited by 2
“Second, definitions vary the dose required to define CC-resistance ranging from 100 mg to 250 mg of CC [20,26,46,50,51].”
BackgroundNeuroendocrinology of Female Reproduction
Wilkinson, M., & Imran, S. A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108149938.004 · Cited by 1
Albar, A. K., Santoso, B. I., Sulistyono, A., & Samsulhadi (2013) · Majalah Obstetri & Ginekologi
Nur, M. S., Santoso, B. I., & Samsulhadi (2013) · Majalah Obstetri & Ginekologi
Punctal ectropion test suture.
Hecht, S. D., & Wiggs, E. O. (1984) · PubMed
Assisted Reproduction Techniques and Acupuncture: Does it works? Literature review
Ruiz, I. O. C., & España, P. F. C. (2018) · Obstetrics & Gynecology International Journal · doi:10.15406/ogij.2018.09.00406
(2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832c937e
Zarei, A., Jahromi, B. N., Madadi, G., Alborzi, M., & Bakhshaei, P. (2022) · Crescent Journal of Medical and Biological Sciences · doi:10.34172/cjmb.2022.28
“The function of such a system is altered in central and peripheral forms (15,16).”
BackgroundCurrent Available Pharmacological Intervention for PCOS-II
Baba, M. S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010006 · Cited by 1
Polycystic ovary syndrome - Effect of acupuncture on insulin resistance and neuroendocrine function
Johansson, J. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Galusca, B., Gay, A., Belleton, G., Eisinger, M., Massoubre, C., Lang, F., Grouselle, D., Estour, B., & Germain, N. (2024) · Figshare · doi:10.6084/m9.figshare.24223882
Galusca, B., Gay, A., Belleton, G., Eisinger, M., Massoubre, C., Lang, F., Grouselle, D., Estour, B., & Germain, N. (2023) · Figshare · doi:10.6084/m9.figshare.24223718
Optimization of conception with intercourse for women with infertility
Boedeker, D., Neumann, B., Vest, A. N., Hill, M. J., Stanford, J. B., & Johnstone, E. B. (2026) · Fertility and Sterility · doi:10.1016/j.fertnstert.2026.04.002
Brinks, A. L., Lawrence, C. N., Kearney, C. A., Rachko, G., Bieber, A. K., DeVore, S., Shapiro, J., Sicco, K. L., & Majerson, D. (2026) · International Journal of Women’s Dermatology · doi:10.1097/jw9.0000000000000275
Varra, F., Theodosis‐Nobelos, P., Varra, V., & Varras, M. N. (2026) · Medicina · doi:10.3390/medicina62081445
Metadata
- Authors
- Ahmed, M. I., Duleba, A. J., El Shahat, O., Ibrahim, M. E., & Salem, A.
- Affiliations
- Benha University (EG)
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-07-29
- Volume
- 23
- Issue
- 11
- Pages
- 2564-2569
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2156291382
- Cited by
- 58
- References
- 53
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 5 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2016: 3 · 2014: 3 · 2013: 7 · 2012: 2
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- naltrexone, polycystic ovary syndrome, clomiphene citrate resistance, opioid system, ovulation induction, infertility, hyperandrogenism, hyperinsulinemia, luteinizing hormone, testosterone, body mass index, pregnancy outcomes
- MeSH terms
- Adolescent, Adult, Analgesics, Opioid, Clomiphene, Drug Resistance, Estrogen Antagonists, Female, Humans, Infertility, Female, Luteinizing Hormone, Naltrexone, Narcotic Antagonists, Polycystic Ovary Syndrome, Pregnancy, Body Mass Index, Pregnancy Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.